1188 related articles for article (PubMed ID: 30586727)
21. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ; Magnuson EA;
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862934
[TBL] [Abstract][Full Text] [Related]
22. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
23. Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA
Roldán V; Rivera-Caravaca JM; Shantsila A; García-Fernández A; Esteve-Pastor MA; Vilchez JA; Romera M; Valdés M; Vicente V; Marín F; Lip GYH
Ann Med; 2018 Feb; 50(1):26-34. PubMed ID: 28892413
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Zelniker TA; Ardissino M; Andreotti F; O'Donoghue ML; Yin O; Park JG; Murphy SA; Ruff CT; Lanz HJ; Antman EM; Braunwald E; Giugliano RP; Merlini PA
Circulation; 2021 Feb; 143(7):673-684. PubMed ID: 33587659
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28729407
[TBL] [Abstract][Full Text] [Related]
26. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
[TBL] [Abstract][Full Text] [Related]
27. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
[TBL] [Abstract][Full Text] [Related]
28. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
29. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
31. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
32. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.
Oldgren J; Hijazi Z; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Granger CB; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Wallentin L;
Circulation; 2016 Nov; 134(22):1697-1707. PubMed ID: 27569438
[TBL] [Abstract][Full Text] [Related]
33. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
de Groot JR; Ruff CT; Murphy SA; Hamershock RA; Vehmeijer JT; Oude Ophuis AJM; Grip L; Lanz H; Mercuri MF; Antman EM; Giugliano RP
Am Heart J; 2021 May; 235():132-139. PubMed ID: 33493453
[TBL] [Abstract][Full Text] [Related]
34. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
[TBL] [Abstract][Full Text] [Related]
35. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
[TBL] [Abstract][Full Text] [Related]
36. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Park S; Bergmark BA; Shi M; Lanz HJ; Chung N; Ruff CT; Antman EM; Braunwald E; Giugliano RP
Hypertension; 2019 Sep; 74(3):597-605. PubMed ID: 31352829
[TBL] [Abstract][Full Text] [Related]
37. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Yin OQP; Antman EM; Braunwald E; Mercuri MF; Miller R; Morrow D; Ruff CT; Truitt K; Weitz JI; Giugliano RP
Circulation; 2018 Oct; 138(18):1963-1973. PubMed ID: 29967197
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S; Lane DA; Buller H; Lip GY
Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
[TBL] [Abstract][Full Text] [Related]
39. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
